Quanren Wang

Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial

Huiping Li, Jieqiong Liu, Quchang Ouyang, Shusen Wang et autres

cn (code pays fourni par la source)

Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study

Lingfang Xia, Keqiang Zhang, Ying Tang, Guonan Zhang et autres

PURPOSE: To compare camrelizumab (an anti-PD-1 monoclonal antibody) plus famitinib (a multitarget receptor tyrosine kinase inhibitor) versus camrelizumab and chemotherapy in recurrent or metastatic cervical cancer (R/M CC). METHODS: Patients with pretreated R/M CC were randomly assigned to receive camrelizumab (200 mg …

cn, hk (code pays fourni par la source)

Overall survival with camrelizumab plus famitinib versus camrelizumab alone and investigator's choice of chemotherapy for recurrent or metastatic cervical cancer

Xiaohua Wu, Lingfang Xia, Keqiang Zhang, Ying Tang et autres

cn (code pays fourni par la source)

A phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-1905, a long-acting anti-thymic stromal lymphopoietin antibody, in healthy subjects

Yue Fei, Na Li, Weilin Qian, Fan Yang et autres

Introduction: Thymic stromal lymphopoietin (TSLP) is integral to inducing innate and T helper two cell inflammation that leads to clinical symptoms of asthma. SHR-1905 is a humanized immunoglobulin G1 kappa monoclonal antibody that inhibits TSLP bioactivity, developed for the treatment of severe …

cn (code pays fourni par la source)

Supplementary Data and Figures from Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

Jianming Xu, Yun Zhang, Ru Jia, Chunyan Yue et autres

1. Inclusion and Exclusion Criteria 2. Study endpoint definitions 3. Appendix Table 1 4. Appendix Figure Legends 5. Method of TMB Analysis

Supplementary Data and Figures from Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

Jianming Xu, Yun Zhang, Ru Jia, Chunyan Yue et autres

1. Inclusion and Exclusion Criteria 2. Study endpoint definitions 3. Appendix Table 1 4. Appendix Figure Legends 5. Method of TMB Analysis

Data from Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

Jianming Xu, Yun Zhang, Ru Jia, Chunyan Yue et autres

AbstractPurpose: This study assessed the safety and efficacy of SHR-1210 (anti-PD-1 antibody) and apatinib (VEGFR2 inhibitor) as combination therapy in patients with advanced hepatocellular carcinoma (HCC), gastric, or esophagogastric junction cancer (GC/EGJC). Patients and Methods: This was an open-label, dose-escalation (phase Ia) …

Data from Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

Jianming Xu, Yun Zhang, Ru Jia, Chunyan Yue et autres

AbstractPurpose: This study assessed the safety and efficacy of SHR-1210 (anti-PD-1 antibody) and apatinib (VEGFR2 inhibitor) as combination therapy in patients with advanced hepatocellular carcinoma (HCC), gastric, or esophagogastric junction cancer (GC/EGJC). Patients and Methods: This was an open-label, dose-escalation (phase Ia) …